Tech Company Financing Transactions

Amplyx Pharmaceuticals Funding Round

On 11/11/2015, Amplyx Pharmaceuticals received $49.2 million in Series B funding from RiverVest Venture Partners, 3x5 Special Opportunity Partners and BioMed Ventures.

Transaction Overview

Announced On
11/11/2015
Transaction Type
Venture Equity
Amount
$49,200,000
Round
Series B
Investors

RiverVest Venture Partners (Lead Investor) (Niall O'Donnell)

3x5 Special Opportunity Partners (Anthony Arnerich)

BioMed Ventures

New Enterprise Associates (Ed Mathers)

Proceeds Purpose
Amplyx will use the funding to advance the clinical development of APX001, the company's broad-spectrum antifungal agent to treat life threatening fungal infections.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
12730 High Bluff Dr. 160
San Diego, CA 92130
USA
Email Address
Overview
Amplyx Pharmaceuticals is developing novel, broad-spectrum antifungal agents for the treatment of life-threatening fungal infections.
Profile
Amplyx Pharmaceuticals LinkedIn Company Profile
Social Media
Amplyx Pharmaceuticals Company Twitter Account
Company News
Amplyx Pharmaceuticals News
Facebook
Amplyx Pharmaceuticals on Facebook
YouTube
Amplyx Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chairman
Michael Grey
  Michael Grey LinkedIn Profile  Michael Grey Twitter Account  Michael Grey News  Michael Grey on Facebook
Chief Executive Officer
Ciara Kennedy
  Ciara Kennedy LinkedIn Profile  Ciara Kennedy Twitter Account  Ciara Kennedy News  Ciara Kennedy on Facebook
Chief Financial Officer
Alan Fuhrman
  Alan Fuhrman LinkedIn Profile  Alan Fuhrman Twitter Account  Alan Fuhrman News  Alan Fuhrman on Facebook
Chief Medical Officer
Michael Hodges
  Michael Hodges LinkedIn Profile  Michael Hodges Twitter Account  Michael Hodges News  Michael Hodges on Facebook
VP - Bus. Development
Kevin Holme
  Kevin Holme LinkedIn Profile  Kevin Holme Twitter Account  Kevin Holme News  Kevin Holme on Facebook
VP - Operations
Paul Bien
  Paul Bien LinkedIn Profile  Paul Bien Twitter Account  Paul Bien News  Paul Bien on Facebook
VP - Operations
Pamela Wedel
  Pamela Wedel LinkedIn Profile  Pamela Wedel Twitter Account  Pamela Wedel News  Pamela Wedel on Facebook
VP - Regulatory Affairs
Elizabeth Gordon
  Elizabeth Gordon LinkedIn Profile  Elizabeth Gordon Twitter Account  Elizabeth Gordon News  Elizabeth Gordon on Facebook


 

 

Browse more venture capital transactions:

Prev: 11/11/2015: ContentOro venture capital transaction
Next: 11/11/2015: EventBoard venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

We do our best to document every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary